vialaudit
SEMAX·US LEGAL STATUS·LAST CHECKED 1 NOV 2026

Is Semax legal?

Not as a drug. Semax has no FDA approval, so selling it for human use breaks federal drug law, and a 'research use only' label does not protect a seller whose site signals human use. It is not a controlled substance, and possessing it is not a federal crime. It is approved in Russia, which has no effect in the US. Under an interim HHS policy of 28 October 2026, a licensed pharmacy may compound it against a prescription, by set routes and under strict conditions, without federal enforcement. That policy does not cover research-use-only vials sold online.

RESEARCH-LABELLED SALE
Unapproved drug
PHARMACY COMPOUNDING
Under conditions · HHS policy Oct 2026
PRESCRIPTION
Not in US · approved in Russia
WADA 2026
Not listed

DESCRIBES THE LAW · NOT LEGAL ADVICE · NO DOSING INFORMATION

Federal, compounding and sport status

CHECKED 1 NOV 2026

Federal status

FDA approval
no approval
DEA scheduling
not scheduled
503A compounding
FDA interim category: Nominated but withdrawn (off Category 2, not eligible)
503A Bulks List: pcac recommended
HHS interim policy (Oct 28, 2026): no enforcement against licensed 503A compounding with a prescription · routes: intranasal only (free base) · FEDERAL REGISTER ↗
Still not on the 503A Bulks List and not an approved drug. Removed from Category 2 on 15 Apr 2026. On 24 Jul 2026 the PCAC recommended it for the Bulks List. On 28 Oct 2026 HHS issued an interim 'Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances' (Federal Register 30 Oct 2026, 91 FR 68526). HHS says it does not intend to take enforcement action against a state-licensed pharmacy, Federal facility or licensed physician compounding Semax against a patient-specific prescription, limited to intranasal only, as a single ingredient, from API made by an FDA-registered facility with a full certificate of analysis. The Federal Register notice calls the policy a draft that is not binding; comments close 13 Nov 2026 (docket HHS-OASH-2026-0496). It does not cover 503B outsourcing facilities or research-use-only vials sold online.
PCAC review history
  • Jul 24, 2026 · recommended · 8 yes, 5 no, 1 abstention (law-firm reports) · SOURCE ↗
FDA Warning Letters
none on record for this compound
Shortage status
not currently on shortage list
Sale framing
Research-use-only posture: Unapproved; FDCA applies. PCAC pending — current status is unapproved with formal review pathway opening.
Personal possession: Not federally criminalized.

Sport-body status

WADA 2026
not prohibited
Not named. Semax is approved in Russia, so S0 does not apply on its text. Check with your anti-doping organisation.
USADA
not banned
NCAA
unknown

What we couldn’t verify

Semax US legal status, checked 12 Oct 2026: research sale Unapproved drug, compounding Not yet · PCAC recommended Jul 2026, prescription Not in US · approved in Russia, WADA 2026 Not listed, 0 FDA warning letters
Semax federal, compounding and sport status, checked 12 Oct 2026. Describes the law, not legal advice.

State rules

1 STATE
compounding restriction · Indiana

Since 1 Jul 2026 Indiana law (IC 16-42-22.5) bars compounding from research-grade or veterinary-grade bulk ingredients outside an IRB-approved study and requires an FDA-registered source with a certificate of analysis. From 1 Jan 2027 medical spas must register with the state medical board. This matters if FDA later allows pharmacies to compound Semax: in Indiana the ingredient could not be research grade.

Semax in Indiana

In the other states we found nothing that names Semax; federal law applies.

What changed at the last check

5 CHANGES
DateFieldWasNowWhy
1 Nov 2026503A compounding (HHS policy)not compoundable; reported HHS stopgap not issuedHHS enforcement discretion under conditions (interim, not on Bulks List)HHS filed its peptide enforcement discretion policy on 28 Oct 2026 (FR doc 2026-22192, published 30 Oct). Semax is one of six peptides in Appendix A. HHS says it will not act against licensed 503A compounding with a prescription, routes limited to intranasal only. Comments close 13 Nov 2026. source ↗
12 Oct 2026503A Bulks List statusunder pcac reviewpcac recommendedNot eligible as of 12 Oct 2026. Removed from Category 2 on 15 Apr 2026; the PCAC recommended it on 24 Jul 2026. source ↗
12 Oct 2026FDA Category 2 (safety risk)under pcac reviewnot on listFDA's Category 2 page lists it under 'nominated but withdrawn', not in Category 2. source ↗
12 Oct 2026IN state notenoneaddedSince 1 Jul 2026 Indiana law (IC 16-42-22.5) bars compounding from research-grade or veterinary-grade bulk ingredients outside an IRB-approved study and requires an FDA-registered source with a certificate of analysis. From 1 Jan 2027 medical spas must register with the state medical board. This matters if FDA later allows pharmacies to compound Semax: in Indiana the ingredient could not be research grade. source ↗
12 Oct 2026PCAC reviewpending (vote scheduled)voted yesPCAC vote on 2026-07-24: 8 yes, 5 no, 1 abstention (law-firm reports). source ↗

Questions

3 ANSWERS
Is Semax legal in the US?

Not as a drug. Semax has no FDA approval, so selling it for human use breaks federal drug law, and a 'research use only' label does not protect a seller whose site signals human use. It is not a controlled substance, and possessing it is not a federal crime. It is approved in Russia, which has no effect in the US. Under an interim HHS policy of 28 October 2026, a licensed pharmacy may compound it against a prescription, by set routes and under strict conditions, without federal enforcement. That policy does not cover research-use-only vials sold online.

Can a pharmacy compound Semax?

Still not on the 503A Bulks List and not an approved drug. Removed from Category 2 on 15 Apr 2026. On 24 Jul 2026 the PCAC recommended it for the Bulks List. On 28 Oct 2026 HHS issued an interim 'Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances' (Federal Register 30 Oct 2026, 91 FR 68526). HHS says it does not intend to take enforcement action against a state-licensed pharmacy, Federal facility or licensed physician compounding Semax against a patient-specific prescription, limited to intranasal only, as a single ingredient, from API made by an FDA-registered facility with a full certificate of analysis. The Federal Register notice calls the policy a draft that is not binding; comments close 13 Nov 2026 (docket HHS-OASH-2026-0496). It does not cover 503B outsourcing facilities or research-use-only vials sold online.

Is Semax banned in sport?

It is not on the WADA 2026 Prohibited List. Not named. Semax is approved in Russia, so S0 does not apply on its text. Check with your anti-doping organisation.

Sources

8 DOCUMENTS
  1. FDA approval record
  2. DEA controlled-substance schedules
  3. HHS peptide enforcement discretion policy, Federal Register
  4. PCAC review, 24 Jul 2026
  5. WADA 2026 Prohibited List
  6. Indiana Senate Enrolled Act 282 (Public Law 136-2026), signed 5 Mar 2026
  7. SEA 282 enrolled text
  8. Source for: FDA Category 2 (safety risk)
THE ROUNDUP · MONTHLY

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 SUBSCRIBERS·0 SPONSORED ITEMS·11 ISSUES SINCE LAUNCH